^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous T-cell Lymphoma |
| Drug: | Zolinza (vorinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
